Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Jensen Huang’s downfall cut the P/E of Nvidia stock by a third. But don’t call it a bargain yet

Wall Street calls it panic selling. But losing the CEO who held off commoditization could justify every dollar of the $2 trillion wipeout.

Jensen Huang’s downfall cut the P/E of Nvidia stock by a third. But don’t call it a bargain yet

Nvidia's stock value plummeted by a third following the resignation of CEO Jensen Huang, who left the company on November 12. This dramatic drop has made Nvidia's shares appear like an historically great investment based on conventional metrics. The GPU company's stock peaked at $243 on October 5, giving it the world's largest market cap at $5.85 trillion.

Analysts were unanimous in their praise for Nvidia's value at that time, as the company was selling at a modest 30 times earnings, compared to its 100% earnings growth rate.

Since October, Nvidia's stock has plummeted 34% to $161, a significant drop that slashed nearly $2 trillion from its valuation. This makes its price-to-earnings ratio (PE) 20, a figure that suggests it is a remarkable value play. For comparison, Apple and Amazon have PE ratios of 40 and 22, respectively, and their growth rates are a fraction of Nvidia's speed.

Despite its impressive size and growth rate, Nvidia has not fallen victim to the law of large numbers. In the quarter ended October 31, Nvidia's sales jumped 26% from the previous three-month period, outperforming the growth rates of the two previous quarters. Moreover, Nvidia's gross margins reached a substantial 75% in the October quarter, surpassing its FY 2026 target of 71.3%.

Written by urgent.news from Fortune's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 3 other outlets

Read the original at fortune.com →

More in Finance & Markets

Why Moderna Stock Dropped on Thursday

Moderna promised 20% sales growth in 2026 -- but Wall Street wants 24%.

  • Moderna's stock dropped 6% in early trading on Thursday.
  • Analyst day revealed revenue growth forecast of 15%-25% for 2026.
  • Concern over rising medium-term cash costs of $4 billion in 2027.

More Good News for Eli Lilly Sends the Stock Even Higher

Lilly's experimental GLP-1 is effective in treating osteoarthritic knee pain.

  • Eli Lilly's stock price surges after positive GLP-1 drug trial results
  • Phase 3 trials at Northwestern show retatrutide reduces OA pain and aids weight loss
  • Partnership with Hims & Hers to expand access to Zepbound and Foundayo

More from Thursday 12 November →